INTRODUCTION
Although this definition is still a matter of debate in the community of Extracellular Vesicles (EV) (Gould and Raposo, 2013) , exosomes are generally defined as secreted vesicles corresponding to the intralumenal vesicles (ILVs) of multivesicular bodies (MVBs), which are formed during the maturation of these endosomes. While some MVBs are fated for degradation, others can fuse with the plasma membrane, leading to the secretion of ILVs as exosomes (Bobrie et al., 2011; Raposo and Stoorvogel, 2013) . The generation of the ILVs into MVBs involves the lateral segregation of cargo at the endosomal limiting membrane, the formation of an inward budding vesicle and the release in the endosomal lumen of the membrane vesicle containing a small portion of cytosol. Over the past 10 years several studies have started to elucidate the mechanisms involved in ILV formation and cargo sorting (Hanson and Cashikar, 2012; Henne et al., 2011; Hurley, 2008; Raiborg and Stenmark, 2009) .
Given that exosomes correspond to ILVs, the same mechanisms are thought to be involved in their biogenesis. However, cells host different populations of MVBs and ILVs (Buschow et al., 2009; Mobius et al., 2003; White et al., 2006) and we are still at an early stage of understanding what are the mechanisms that contribute to exosome formation and cargo sorting within these vesicles.
The components of the Endosomal Sorting Complex Required for Transport (ESCRT) are involved in MVB and ILV biogenesis. ESCRTs comprise approximately twenty proteins that assemble into four complexes (ESCRT-0, -I, -II and -III) with associated proteins (VPS4, VTA1, ALIX) conserved from yeast to mammals (Henne et al., 2011; Roxrud et al., 2010) .
The ESCRT-0 complex recognizes and sequesters ubiquitinated proteins in the endosomal membrane, whereas the ESCRT-I and -II complexes appear to be responsible for membrane deformation into buds with sequestered cargo and ESCRT-III components subsequently drive vesicle scission (Hurley and Hanson, 2010; Wollert et al., 2009) . ESCRT-0 consists of HRS that recognizes the mono-ubiquitinated cargo proteins and associates in a complex with STAM, Eps15 and clathrin. HRS recruits TSG101 of the ESCRT-I complex, and ESCRT-I is then involved in the recruitment of ESCRT-III, via ESCRT-II or ALIX, an ESCRT-accessory protein. Finally, the dissociation and recycling of the ESCRT machinery requires interaction with the AAA-ATPase Vps4. It is unclear whether ESCRT-II has a direct role in ILV biogenesis or if its function is limited to a particular cargo (Bowers et al., 2006; Malerod et al., 2007) .
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Concomitant silencing of ESCRT subunits belonging to the four ESCRT complexes does not totally impair the formation of MVBs, indicating that other mechanisms may operate in the formation of ILVs and thereby of exosomes (Stuffers et al., 2009) . One of these pathways requires a type II sphingomyelinase that hydrolyses sphingomyelin to ceramide (Trajkovic et al., 2008) . Whereas the depletion of different ESCRT components did not lead to a clear reduction in the formation of MVBs and in the secretion of PLP via exosomes, silencing of neutral sphingomyelinase expression with siRNA or its activity with the drug GW4869 decreased exosome formation and release. However, whether such dependence on ceramide is generalizable to other cell types producing exosomes and additional cargos has not been further strengthened. The depletion of type II sphingomyelinase in melanoma cells does not impair MVB biogenesis (van Niel et al., 2011) or exosome secretion (our unpublished data) but in these cells the tetraspanin CD63 is required for an ESCRT-independent sorting of the luminal domain of the melanosomal protein PMEL (van Niel et al., 2011) . Moreover, tetraspanin-enriched domains have been recently proposed to function as sorting machineries towards exosomes (Perez-Hernandez et al., 2013) .
Despite evidences for ESCRT-independent mechanisms for exosome formation, proteomic analyses of purified exosomes, from various cell types, show the presence of ESCRT components (TSG101, ALIX) and ubiquitinated proteins (Buschow et al., 2005; Thery et al., 2001 ). It has also been reported that the ESCRT-0 component HRS could be required for exosome formation/secretion by dendritic cells (DCs), and thereby impact on their antigen presenting capacity (Tamai et al., 2010) . The Transferrin Receptor (TfR) in reticulocytes that is generally fated for exosome secretion, although not ubiquitinated, interacts with ALIX for MVB sorting (Geminard et al., 2004) . More recently it was also shown that ALIX is involved in exosome biogenesis and exosomal sorting of syndecans via its interaction with syntenin (Baietti et al., 2012) .
Nonetheless, as discussed above and elsewhere (Bobrie et al., 2011) and mostly because in most studies only one or few selected ESCRT subunits and accessory proteins have been analysed, it is still unclear whether ESCRT components could be involved at any step of the formation of exosomes. Here, we have used RNA interference (RNAi) to target twenty-three different components of the ESCRT machinery and associated proteins in MHC II-expressing HeLa cells. To specifically analyse the effect of these ESCRT components on secretion of MVB-derived vesicles (i.e. exosomes), we characterized and quantified the released vesicles by their content in the endosomal tetraspanins CD63, Major Histocompatibility Complex class II molecules (MHC II) and either the endosome-associated heat shock protein HSC70, or the tetraspanin CD81. Our results demonstrate a role for a few selected members of this family in either the efficiency of secretion or the size and composition of the secreted vesicles. In addition, they highlight differences in exosomes secreted by these cells and primary MHC II-expressing DCs, in terms of size and content of some exosomal proteins.

RESULTS
Selected ESCRT proteins modulate exosome biogenesis or secretion
In order to determine whether different ESCRT components affect exosome biogenesis or secretion, we performed a small hairpin RNA (shRNA)-based screen targeting twenty-three ESCRT proteins in a 96-well plate format as previously set up in our group (Ostrowski et al., 2010) . HeLa-CIITA-OVA cells were used as a model cell line, since they express MHC II molecules which allow us to monitor exosome secretion, and they secrete ovalbumin (OVA) which is useful to assess the classical secretion pathway. These cells were infected with lentiviral vectors encoding for shRNA sequences specific for individual ESCRT proteins: five different shRNA sequences were used to knockdown each gene, and the control was an shRNA which does not target any human sequences (shSCR). shRNA-expressing cells selected by puromycin were incubated for 48 h with medium depleted from serum-derived exosomes. Secreted exosomes were then trapped on anti-CD63 coated beads (because CD63 accumulates on ILVs of MVBs in HeLa-CIITA (Ostrowski et al., 2010) ) and detected by flow cytometry with anti-CD81 and anti-HLA-DR (MHC II) antibodies, two molecules commonly detected in most EVs (Escola et al., 1998; Zitvogel et al., 1998) . To monitor the classical secretory pathway of soluble proteins, ovalbumin was similarly trapped on anti-OVA beads and detected with an anti-OVA antibody ( Figure 1A) . Finally, the efficiency of the silencing of each gene was analysed in exosome-secreting cells by quantitative RT-PCR (qRT-PCR).
The criteria defined for a gene to be potentially involved in exosome secretion was that at least two different shRNA sequences, which inhibited gene expression either significantly or by at least 50%, would modulate exosome secretion in the same manner. In addition, only shRNA that did not affect cell proliferation or survival were considered for further analysis.
The results of the screen are summarized in Table 1: among the 23 candidates analysed, seven were not further analysed for effects on exosome secretion due to the inability to demonstrate a down-regulation of the gene. shRNA specific for four of the candidates did not induce a significant modulation of exosome secretion ( Figure S1 ), and five of them showed inconsistent effects of the different shRNA sequences on exosome secretion ( Figure S2 ). Therefore, we are not able to conclude on the involvement of these 16 genes in exosome secretion.
The remaining seven candidates met the defined selection criteria; a second round of screening then confirmed selected hits. As shown in Figure 1B , inhibiting three ESCRT-0/I proteins (HRS, STAM1 and TSG101) induced a decrease in exosome secretion: two or more different shRNA sequences (sh1 and sh3 for HRS, sh2 and sh3 for STAM1, all shRNA for TSG101) induced at least 50% inhibition in exosome secretion. Conversely, inhibition of four ESCRT-III, disassembly and accessory proteins (CHMP4C, VPS4B, VTA1, ALIX) induced an increase in exosome secretion ( Figure 1C ): at least two shRNA sequences (sh3 and sh5 for CHMP4C and VPS4B, sh1 and sh3 for VTA1 and ALIX) induced an increase of 50% or more in exosome secretion as measured by our FACS-based assay. Both sh1 and sh3 targeting ALIX, were selected as candidate sequences because, despite that sh4 decreased more than the other sequences the level of ALIX expression, only sh1 and sh3 lead to a similar phenotype of increased secretion of exosomes. Secretion of OVA was not affected by most shRNA sequences upon depletion of HRS, STAM1, TSG101, VTA1 and ALIX. Silencing of CHMP4C and VPS4B induced a significant increase (over 100% in the case of VPS4B, and between 50 and 80% for CHMP4C) in secreted OVA with most shRNA sequences. These data suggest that these components may also have an impact on the classical secretion pathway of proteins.
Validation of the screen results by Western blot analysis of secreted exosomes
We then chose one shRNA to validate the results of the screen, by analysing exosomes produced by large numbers of cells (1-2x10 8 cells), using classical purification procedures (Thery et al., 2006) . Of the two shRNA that modulated exosome secretion in the same manner (listed in the previous section), we selected the one that induced the highest mRNA decrease (sh3 for HRS, CHMP4C and VPS4B, sh2 for STAM1, sh1 for TSG101, VTA1 and ALIX).
Exosomes were purified by differential ultracentrifugation of the supernatant of shRNAexpressing HeLa-CIITA-OVA cells as previously described (Thery et al., 2006) , and the pellet obtained in the final 100,000xg ultracentrifugation was analysed by Western blotting for the presence of MHC II, CD63 and a chaperone described previously as enriched in exosomes secreted by mouse DCs, HSC70 (Thery et al., 1999) (Figures 2A-D and S3) . Three experiments were performed, in which we also assessed the efficient down-regulation of each target gene by qRT-PCR or Western blotting of total cell lysates ( Figure S4 ).
As compared to control cells, secretion of all markers was decreased in HRS, STAM1 and TSG101-depleted cells, which suggests a decrease in total exosome secretion by these cells.
In the case of CHMP4C and VTA1 depletion, we observed no change, or even a slight decrease, in the signal of all three markers, which does not confirm the initial conclusion from the screen, where we detected an increase in exosome secretion ( Figure 1C ). VPS4B silencing induced an increase in all markers as compared to exosomes from shSCR-treated cells, which
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indicates an increase in total secretion of exosomes, in agreement with the results from the screen. Interestingly, the silencing of ALIX caused a clear increase in MHC II in the three experiments, but showed more variable effects on the levels of HSC70 and CD63 as compared to control exosomes. These results suggest a change in exosome composition due to ALIX depletion, rather than a change in exosome yield.
To confirm the effects of gene depletion observed with one shRNA, a similar Western blot analysis of exosomes secreted in a large scale set up was performed using the other shRNA displaying a similar effect in the screen (Figure 1 ). This further confirmed that inhibiting these genes by two different shRNA sequences respectively decreased (HRS, STAM1, TSG101) or increased (VPS4B) overall exosome secretion ( Figure 2E ).
Immuno-electron microscopy (IEM) analysis of exosomes released by ESCRT-depleted cells
To investigate the morphology and CD63 / MHC II content of the vesicles secreted by shRNA-treated cells as compared to control cells, we characterized exosomes by IEM in a quantitative manner: 100,000xg pellets were analysed as whole mounted samples immunogold-labelled for MHC II and CD63 ( Figure 3A) . The diameter and the amount of gold particles corresponding to each marker were evaluated for 200 individual vesicles per condition. First, we observed that the proportion of vesicles of different sizes was modified upon silencing of some ESCRT components ( Figure 3B ). The majority of vesicles from shSCR, shVPS4B or shTSG101 cells displayed a diameter of 50 to 100 nm ( Figure 3B , upper panel). By contrast, shHRS slightly increased the proportion of smaller vesicles (below 50 nm, Figure 3B , middle panel), whereas silencing of STAM1 or ALIX increased the proportion of larger vesicles (above 100 nm, Figure 3B , lower panel).
By quantifying the presence of CD63 and MHC II in vesicles of different sizes, we observed that CD63 was most enriched on smaller vesicles, whereas MHC II was detected more prominently in larger vesicles, and vesicles bearing both proteins represented on average less than 20% of the total vesicles ( Figure 3C ). It should be noted, however, that absence of labelling does not imply that these proteins are completely absent, only that their level is too low to be detected. These observations indicate that, in addition to vesicles with a classical We have thus so far observed an important heterogeneity of the vesicles purified by the differential ultracentrifugation procedure classically used for exosome purification, not only in terms of size but also of protein content. Interestingly, depletion of HRS and STAM1
induced a general decrease in secretion of vesicle-associated CD63 and MHC II (as observed by Western blotting) ( Figure 2 ). With the former, however, the vesicles were also of smaller size, whereas with the latter they were larger than control vesicles. The most remarkable effect was observed upon silencing of ALIX, which induced the secretion of an increased proportion of larger vesicles, and an altogether higher MHC II content.
ALIX-depleted HeLa cells display a higher MHC II content
In order to understand the effect induced by shALIX on exosomes secreted by HeLa-CIITA-OVA cells, we analysed total cell lysates by Western blotting ( Figure 4A ): we confirmed the decrease of ALIX in shRNA-expressing cells, and we quantified an increase in MHC II content in these cells (between 25 and 140%) as compared to reference proteins (HSC70 or Actin depending on the experiment). The MHC II increase in ALIX-depleted cells was also observed at the cell surface, as shown by FACS staining of non-permeabilised cells ( Figure   4B ), whereas the levels of CD63 were on average not significantly modified as compared to control cells. Finally, quantitative IEM analysis of ultrathin cryosections labelled for MHC II and CD63 ( Figure 4C ) showed that the labelling for MHC II molecules was higher, whereas the labelling for CD63 was unaltered, in the MVBs of cells silenced for ALIX, as compared to control cells. We have thus observed a general increase of MHC II in cells upon ALIX knockdown, both at the cell surface and in intracellular MVBs.
This overexpression could be due to an increased transcription of the MHC II genes, translation of the mRNA, or stability of the protein (i.e. less degradation). To test the first hypothesis, we performed reverse transcription followed by qRT-PCR on mRNA extracted from shSCR or shALIX-treated cells. As shown in Figure 5A , upon ALIX silencing we
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observed an increase of at least 50% and generally more than 200% in the expression of MHC II beta (HLA-DRB1) and alpha (HLA-DRA) chains, whereas CD63 mRNA was modulated in a variable manner, showing a slight increase in only half of the experiments. We then reexpressed ALIX in shALIX-expressing cells, using a cDNA bearing silent mutations in the shRNA-binding site, and observed a resulting decrease of HLA-DR mRNA level, although not at the same levels as the shSCR control cells, which can be expected for a rescue experiment ( Figure 5B ). These results indicate that ALIX modulates HLA-DR expression at the mRNA level, showing an unexpected effect of ALIX on mRNA expression or stability.
Silencing of ALIX results in an increase in MHC II content in human immature DCs
We next asked if the increase in MHC II induced by shALIX (sh1) in the HeLa-CIITA cells and their exosomes was also observed in cells that endogenously express MHC II molecules.
We analysed human monocyte-derived DCs, since their exosomes can induce immune responses and are currently used in a clinical trial (Viaud et al., 2011; Zitvogel et al., 1998) . 
ALIX depletion does not increase MHC II secretion on DC exosomes
The observation that ALIX depletion increased MHC II expression in DCs led us to further investigate whether this also resulted in the secretion of MHC II-enriched exosomes. We first performed the FACS-based CD63-mediated capture assay used in the screen (see Figure 1A ). Figure 7A shows the results obtained with immature DCs treated with shALIX from seven different donors (the same donors as in Figure 6 ), expressed as percent of the corresponding shSCR, set to 100%. We did not observe a significant increase in the signal measured with the FACS-based assay: only 2/7 experiments (donors 3 and 6) showed a slight increase, albeit much lower (less than 50%) than the one found with HeLa-CIITA cells (around 75-100%).
The other experiments showed no effect (donor 4), or a decrease of 50% or higher (donors 1, 2, 5 and 7). These results suggest that the relative composition of MHC II, CD63 and CD81 in exosomes secreted by DCs could be distinct from that of HeLa-derived exosomes, and different between donors. We thus tested by IEM DC-derived EVs obtained by 100,000xg ultracentrifugation, as done for HeLa-CIITA ( Figure 7B ). Vesicles obtained from 3 independent non-shRNA treated DC preparations were analysed: pooled results are shown in (Harding et al., 1983; Pan et al., 1985) , in EBV-B lymphocytes (Raposo et al., 1996; Wubbolts et al., 2003) and DCs (Zitvogel et al., 1998; Buschow et al., 2009) , as well as more recent findings in the HeLa-CIITA cell model (Ostrowski et al., 2010) support an endosomal origin of exosomes. Since they correspond to the internal vesicles of MVBs, candidate targets for intervention on their biogenesis and secretion are mechanisms supposed to be involved in cargo sequestration at the endosomal membrane and vesicle budding and scission. The discovery that the ESCRT machinery was involved in MVB formation (Henne et al., 2011; Raiborg and Stenmark, 2009 ) opened a new avenue to interfere with the formation of ILVs and thereby exosome secretion. However the evidence that ESCRT-independent mechanisms also operate for the biogenesis of MVBs and sorting of components to ILVs (Theos et al., 2006; Trajkovic et al., 2008; Stuffers et al., 2009; vanNieletal.,2011) suggested that these mechanisms could be broader and therefore more complex and redundant that initially envisioned.
In this study we set out to investigate for the first time the involvement of a large panel of ESCRT components (twenty-three genes in total) in exosome biogenesis and secretion in HeLa-CIITA cells. For this purpose, we performed a screening using a FACS-based assay, which allows relative quantification of exosomes secreted in the supernatant of cells treated with small hairpin RNA. Since exosomes have been previously described as enriched in tetraspanins and MHC II molecules, we designed this assay to quantify the population of vesicles bearing CD63 and either CD81 or MHC II, which we assumed would correspond most specifically to vesicles originating from endosomes. Of note, this readout obviously provides information on a selected fraction of all secreted exosomes, since it does not take into account vesicles bearing CD63 but none of the other two proteins. In addition, combined detection of two distinct proteins, MHC II and CD81, to allow relative quantification of captured exosomes during the screen may have masked subtle effects of some shRNA, e.g. on specific incorporation of only one of these proteins in exosomes, or on specific release of a subpopulation of vesicles bearing only one of them. As for any shRNA screen, we can only firmly conclude that the four genes for which strong positive effects were observed in the (Fevrier et al., 2004; Mobius et al., 2002; White et al., 2006) . In addition, we also show here that extracellular vesicles recovered from human primary DCs are more heterogeneous in size and protein composition than those secreted by HeLa-CIITA (Figure 7) , and also vary from one donor to the other ( Figure S6 ). These observations suggest that DCs from different donors secrete variable proportions of vesicles derived either from intracellular compartments (exosomes) or possibly from the plasma membrane. Thus, proteins specifically enriched in the different subpopulations of vesicles will have to be identified in the future, to allow the development of other capture-based assays to identify the molecular machinery involved in their respective secretion.
Our work conclusively shows that silencing of two components of ESCRT-0 (HRS, STAM1) and one of ESCRT-I (TSG101), as well as a late acting component (VPS4B)
induced consistent alterations in exosome secretion. Previous studies on an oligodendrocytic cell line secreting the proteolipid PLP in association with exosomes highlighted a formation and release process independent of ESCRT function but requiring the production of the lipid ceramide by a type II sphingomyelinase (Trajkovic et al., 2008) . In this study, silencing of HRS, TSG101, ALIX and VPS4 did not alter consistently the sequestration of PLP in ILVs of MVBs, although it reduced the trafficking of Epidermal Growth Factor (EGF) and its receptor to MVBs. However, our data clearly show that secreted exosomes are heterogeneous on the basis of their size and cargo, and since this previous study only followed one population (i.e.
PLP-containing exosomes) in a given cell type, it is in our opinion difficult to extrapolate that all exosome populations are ESCRT-independent. As suggested before by an extensive and that ALIX depletion results in reduced exosome secretion (Baietti et al., 2012) . Our results do not challenge these findings but rather put forward the idea that, depending on the cell types and the cargoes associated with different exosome subpopulations, the mechanisms involved may slightly change. Indeed, when we analysed exosome secretion by DCs, our CD63-mediated exosome capture assay failed to evidence increased secretion of MHC IIbearing exosomes upon ALIX depletion. On the contrary, a decreased secretion in the majority of donors was observed ( Figure 7A ). This could suggest either that EVs secreted by ALIX-inactivated DCs did not present an increase in MHC II at their surface despite the overall overexpression of MHC II in the secreting cells, or that secretion of CD63-bearing exosomes was decreased in ALIX-impaired DCs, which was compensated by the increased amount of MHC II on these exosomes. In any case, the difference between DCs and MHC II- In conclusion, our findings altogether reinforce the concept that cells host different subpopulations of MVBs and secrete a heterogeneous population of exosomal vesicles.
Whereas ESCRT-independent mechanisms are involved in MVB/exosome biogenesis (Trajkovic et al., 2008; van Niel et al., 2011) , our observations and recent reports (Baietti et al., 2012; Tamai et al., 2010) show that the formation and secretion of a population of exosomes also rely on the function of ESCRTs and accessory proteins, and that only selected components may be involved in protein sorting and the formation of the ILVs fated to be secreted as exosomes. These observations will certainly contribute to our understanding of the mechanisms involved in exosome formation and will open an avenue for modulating the nature of exosomes and their composition.
MATERIALS AND METHODS
Cells and reagents
HeLa-CIITA OVA cells (subclone B6H4, (Ostrowski et al., 2010) were cultured in DMEM containing 4.5 g/L glucose (Life Technologies) 10% fetal calf serum (FCS, Gibco or PAA), 100 IU/mL penicillin and 100 µg/mL streptomycin (Gibco), 300 µg/mL hygromycin B (Calbiochem) and 500 µg/mL geneticin (Life Technologies). Medium depleted from FCSexosomes (exosome-depleted medium) was obtained by overnight ultracentrifugation of complete medium at 100,000xg (Thery et al., 2006) .
Lentiviruses expressing shRNA and a puromycin resistance gene were obtained from the RNAi consortium (TRC) and produced as described previously (Moffat et al., 2006) . As a control, the scrambled sequence of shRNA to GFP (not targeting any human gene) was used (shSCR). Sequences of shRNA are given in supplementary Table S1 . For rescue experiments, a cDNA encoding human ALIX with silent mutations in the shRNA-binding domains (Table   S1 ) was designed and purchased from Genscript cloned in the pcDNA3.1/Zeo expression plasmid (Life Sciences).
Antibodies used for FACS analysis of bead-captured exosomes were: mouse anti-human 
Screening procedure
For each independent experiment, HeLa-CIITA-OVA were newly infected with shRNAexpressing lentiviruses. The screen was performed as previously described (Ostrowski et al., Journal of Cell Science Accepted manuscript The mean of 9 values from three independent experiments is shown in Figures 1, S1 , and S2.
RNA extraction and real-time qPCR
RNA was extracted from cells in each well with the RNA XS kit or from 5x10 5 -10 6 cells with the RNA II kit (Macherey Nagel). Reverse transcription and quantitative real-time PCR were performed as described previously (Bobrie et al., 2012) , using primers purchased from Qiagen (QuantiTect Primer Assay). Gene expression was normalized to the level of GAPDH or ACTIN expression.
Exosome purification
For each condition 5x10 7 cells were plated in exosome-depleted medium and incubated for 48h. Supernatants were then harvested and exosome purification was performed as previously described (Thery et al., 2006) . Cell number after cell detachment from all the dishes was determined using an automated Countess cell counter (Life Technologies), and was similar in all experimental conditions. Supernatants were centrifuged at 300xg for 5 min to eliminate floating cells, at 2,000xg for 20 min to remove cell debris, and at 10,000xg for 40 min to separate microvesicles. An ultracentrifugation step at 100,000xg for 90 min was performed to obtain exosomes, followed by a washing step in PBS to eliminate contaminating proteins.
Exosomes were resuspended in 100 µL PBS, and protein content was measured by
MicroBCA (Pierce) in the presence of 2% SDS.
Western blotting
A volume of exosomes secreted by 30x10 6 cells, or 100 µg of total cell lysate were used for Western blotting. Western blotting and quantifications were performed as previously described (Bobrie et al., 2012) . For each independent experiment, vesicles secreted by the different shRNA-expressing cells were analysed on gels and membranes processed simultaneously.
Flow cytometry analysis
For surface staining, cells were harvested and incubated with anti-MHC II or CD63 antibody (2 µg/mL) for 30 min on ice, followed by anti-mouse-Alexa488 antibody (1/200) for 20 min on ice, and acquisition on a MACSQuant flow cytometer.
Electron microscopy
Exosomes resuspended in PBS were deposited on formvar-carbon coated copper/palladium grids for whole-mount IEM analysis as previously described (Thery et al., 2006; Raposo et al., 1996) . For double labelling, samples on grids were successively incubated with mouse anti-MHC II, protein A-gold (PAG) 15 nm (PAG15), glutaraldehyde 1% (Electron Microscopy Sciences), anti-CD63, PAG10 and glutaraldehyde, before being contrasted and embedded in a mixture of methylcellulose/uranyl acetate.
Transduced cells were fixed in 0.2M phosphate buffer (pH 7.4) with 2% PFA and 0,125% glutaraldehyde for 2 h at RT. Cells were then processed for ultrathin cryosectioning as previously described , and labelled with rabbit anti-MHC II (1/200) or anti-CD63 (2 µg/mL) antibodies, followed by PAG15 and PAG10, respectively.
Samples were observed at 80kV with a CM120 Twin FEI electron microscope (FEI Company, Eindoven, Netherlands) and digital images were acquired with a numeric camera (Keen View, Soft Imaging System, Germany). Quantification was performed with the iTEM software (Soft imaging System). For exosome quantifications, one area of the grid was chosen randomly at low magnification and one image was obtained by multiple image acquisition (comprising nine individual micrographs). For all cell analysis after immunogold labelling on ultrathin cryosections, labelling for MHC II and CD63 in MVBs was quantified in 50 compartments taken randomly in electron micrographs acquired at the same magnification.
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Rescue experiments
HeLa-CIITA-OVA cells were infected with shRNA-expressing lentiviruses, treated 36h later with 5 µg/mL puromycin, and plated after 36h in 6 well plates (2.5x10 5 cells/ well). The next day, cells were transfected with the TransIT-LT1 transfection reagent (Mirus) and 2.5 µg/ well of pcDNA3.1/Zeo (Life Sciences) or the same plamid expressing human ALIX with silent mutations in the shRNA-binding domains, according to the manufacturer's recommendations. Cells were harvested 72h after transfection for RNA extraction and subsequent reverse transcription and qRT-PCR (see above).
Dendritic cell transduction and FACS assay
Monocyte-derived DCs were obtained from blood samples of healthy donors. This study was conducted according to the Helsinki Declaration, with informed consent obtained from the blood donors, as requested by our Institutional Review Board. PBMC were isolated by density gradient centrifugation (LymphoPrep, Axis-Shield), CD14 + monocytes were obtained by magnetic sorting (Miltenyi Biotec) and cultured in RPMI 1640 (Gibco) supplemented with 10% FCS (Biowest), 50 mM 2-ME, 10 mM HEPES, 100 IU/mL penicillin and 100 µg/mL streptomycin (Gibco), with 50 ng/mL IL-4 and 100 ng/mL GM-CSF (Miltenyi Biotec).
Monocytes were transduced with shSCR or shALIX according to the protocol by Satoh and Manel (Satoh and Manel, 2013) . Briefly, HEK293T cells were transfected with plasmids pLKO.1, pΔ8.9, pCMV-VSV-G and TransIT-LT1 transfection reagent (Mirus Bio) to generate a lentiviral vector carrying an shRNA sequence and the puromycin resistance gene; or with plasmids pSIV3 + and pCMV-VSV-G to generate helper particles containing the Vpx protein which overcomes the blocking of lentiviral infections normally observed in monocytederived DCs (Goujon et al., 2006) . Fresh monocytes were incubated with equal volumes of both particles and 8 µg/mL protamine for 48h, and incubated with fresh medium with 2 µg/mL puromycin for 72h. Immature DCs thus obtained were incubated at 2x10 5 cells per well in exosome-depleted medium for 24h (in triplicates) to detect secreted exosomes by trapping on beads followed by staining for flow cytometry, as described above. Maturation was induced by treating DCs with LPS (1 μg/mL, Sigma) and IFN-γ (2500 IU/mL, Miltenyi Biotec). To check DC differentiation and maturation status, multicolour FACS analysis was performed, using anti-HLA-DR-APC / anti-CD86-FITC / anti-CD81-PE, anti-CD63-FITC / anti-CD80-PE, or anti-CD14-PE / anti-CD1a-PECy5 (1/100, BD Biosciences except anti-CD63, BioLegend) or the corresponding isotype controls (1/100, BD Biosciences).
Statistical analysis
Statistical tests were performed with GraphPad Prism software (GraphPad Software, Inc.).
Screening results were analysed by one-way ANOVA followed by Tukey's post-hoc test.
Western blot and FACS analyses comparing shRNA-treated cells with shSCR = 100%, were analysed by a Wilcoxon Signed Rank Test comparing the medians to a hypothetical value of 100. Percentages of CD86-positive DCs ( Figure S5B ) were compared by a paired t-test.
Values are shown as mean ± s.d. in figures 1, 7, S1 and S2, or as median in figures 2, 4, 5, 6
and S4.
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